{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-002555","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.815463+00:00","generated_at":"2026-05-28T08:50:30.849019+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MBX Biosciences announces positive Phase 1 topline results for MBX 1416 for PBH; cash $262.1M","bullets":["MBX 1416 generally well-tolerated; no dose-related serious adverse events; mild/moderate ISRs in 88% resolved ~7 days.","Median half-life ~90 hours supports once-weekly dosing; Tmax 36-48h at steady state; dose-proportional PK.","GLP-1 increase within 60 mins of mixed meal test; slight acceleration of gastric emptying observed.","No meaningful effect on rosuvastatin exposure in drug-drug interaction portion.","Phase 2 in PBH patients expected to start 2H 2025; cash $262.1M as of Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-002555","json":"https://secwatch.observer/filing/0000950170-25-002555.json","markdown":"https://secwatch.observer/filing/0000950170-25-002555.md","text":"https://secwatch.observer/filing/0000950170-25-002555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025002555/0000950170-25-002555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025002555/mbx-20250107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T08:50:30.849019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}